ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v12i1.1245ppharm-461Research ArticleЛЕКЦИЯLECTUREКИШЕЧНАЯ МИКРОБИОТА И ИСПОЛЬЗОВАНИЕ ПРОБИОТИКОВ В ПРАКТИКЕ ПЕДИАТРА. ЧТО НОВОГО?INTESTINAL MICROBIOTA AND USE OF PROBIOTICS IN PEDIATRIC PRACTICE: NEWSМакароваС. Г.MakarovaS. G.

доктор медицинских наук, главный научный сотрудник отдела по клиническим исследованиям в педиатрии ФГБНУ «Научный центр здоровья детей», профессор кафедры аллергологии и клинической иммунологии Первого МГМУ им. И.М. Сеченова

sm27@yandex.ruНамазова-БарановаЛ. С.Namazova-BaranovaL. S.Научный центр здоровья детей, Москва, Российская Федерация Первый Московский медицинский государственный университет им. И.А. Сеченова, Москва, Российская ФедерацияРоссияScientific Center of Children's Health, Moscow, Russian Federation Sechenov First Moscow Medical State University, Moscow, Russian FederationRussian FederationНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский медицинский государственный университет им. И.А. Сеченова, Москва, Российская Федерация Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва, Российская ФедерацияРоссияScientific Center of Children's Health, Moscow, Russian Federation Sechenov First Moscow Medical State University, Moscow, Russian Federation Pirogov Russian National Medical Research University, Moscow, Russian FederationRussian Federation2015210820151213845Copyright © Макарова С.Г., Намазова-Баранова Л.С., 20152015Макарова С.Г., Намазова-Баранова Л.С.Makarova S.G., Namazova-Baranova L.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/461

Состояние кишечной микробиоты является важнейшим фактором здоровья ребенка. Как показывают последние исследования, индивидуальность и определенное постоянство микробиоты каждого человека во многом определено генетически, в то же время микробиоценоз чутко реагирует на любые внешние воздействия, что характеризует его лабильность. В статье приведены новые данные о составе и функции кишечной микрофлоры, а также о характере взаимодействия в системе микробиоценоз–хозяин. Кишечная микрофлора оказывает непосредственное влияние на формирование иммунной системы ребенка, обеспечивает защиту от патогенов, участвует во всех видах обмена. Рассматриваются современные подходы к модулированию микробиоты кишечника и применению пробиотиков с целью профилактики и лечения различной патологии в педиатрической практике.

Condition of intestinal microbiota is a key factor of a child's health. According to the latest studies, distinctness and certain stability of every person's microbiota is to a large extent determined genetically; at the same time, microbiocenosis is sensitive to external exposure, i.e. it is labile. The article presents new data on the intestinal microflora's composition and function, as well as on the nature of interaction in the microbiocenosis-host system. Intestinal microflora directly affects formation of a child's immune system, ensures protection from pathogens and takes part in all types of metabolism. The article presents modern approaches to intestinal microflora modulation and use of probiotics to prevent and treat various pathologies in pediatric practice.

микрофлора кишечникамикробиотапитаниедетипробиотикипребиотикилактобактериииммунная система ребенкаintestinal microfloramicrobiotanutritionchildrenprobioticsprebioticslactobacteriachild's immune systemReferencesMethe B. A., Nelson K. E., Pop M., Creasy H. H., Giglio M. G., Huttenhower C., Gevers D., Petro- sino J., Abubucker S., Badger J. H., Chinwalla A. T., Ear A. M., FitzGerald M. G., Fulton R. S., Hallsworth Pepin K., Lobos E. A., Madupu R., Magrini V., Martin J. C., Mitreva M., Muzny D. M., Sodergren E. J., Versalovic J. A framework for human microbiome research. Nature. 2012; 486: 215–221.Methe B.A., Nelson K.E., Pop M., Creasy H.H., Giglio M.G., Huttenhower C., Gevers D., Petro- sino J., Abubucker S., Badger J.H., Chinwalla A.T., Ear A.M., FitzGerald M.G., Fulton R.S., Hallsworth-Pepin K., Lobos E.A., Madupu R., Magrini V., Martin J.C., Mitreva M., Muzny D.M., Sodergren E.J., Versalovic J. A framework for human microbiome research. Nature. 2012; 486: 215–221.Huttenhower C., Gevers D., Knight R., Abu-bucker S., Badger J. H., Chinwalla A. T., Creasy H. H., Earl A. M., FitzGerald M. G., Fulton R. S., Giglio M. G., Hallsworth-Pepin K., Lobos E. A., Madupu R., Magrini V., Martin J. C., Mitreva M., Muzny D., Sodergren E., Versalovic J., Wollam A. M., Worley K. C., Wortman J. R., Young S. K., Zeng Q., Aagaard K. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486: 207–214.Huttenhower C., Gevers D., Knight R., Abu-bucker S., Badger J.H., Chinwalla A.T., Creasy H.H., Earl A.M., FitzGerald M.G., Fulton R.S., Giglio M.G., Hallsworth-Pepin K., Lobos E.A., Madupu R., Magrini V., Martin J.C., Mitreva M., Muzny D., Sodergren E., Versalovic J., Wollam A.M., Worley K.C., Wortman J.R., Young S.K., Zeng Q., Aagaard K. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486: 207–214.Kau A. L., Ahern P. P., Griffin N. W., Goodman A. L., Gordon J. I. Human nutrition, the gut microbiome and the immune system. Nature. 2011; 474 (7351): 327–36.Kau A.L., Ahern P.P., Griffin N.W., Goodman A.L., Gordon J.I. Human nutrition, the gut microbiome and the immune system. Nature. 2011; 474 (7351): 327–36.Goodacre R. Metabolomics of a superorganism. J Nutr. 2007; 137 (Suppl. 1): 259S–266S.Goodacre R. Metabolomics of a superorganism. J Nutr. 2007; 137 (Suppl. 1): 259S–266S.Claesson M. J., Jeffery I. B., Conde S., Power S. E., O’Connor E. M., Cusack S., Harris H. M., Coakley M., O’Sullivan O., Fitzgerald G. F., Deane J., O’Connor M., Harnedy N., O’Connor K., O’Mahony D., van Sinderen D., Wallace M., Brennan L., Stanton C., Marchesi J. R., Fitzgerald A. P., Shanahan F., Hill C., Ross R. P., O’Toole P. W. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012; 488 (7410): 178–84.Claesson M.J., Jeffery I.B., Conde S., Power S.E., O’Connor E.M., Cusack S., Harris H.M., Coakley M., O'Sullivan O., Fitzgerald G.F., Deane J., O'Connor M., Harnedy N., O'Connor K., O'Mahony D., van Sinderen D., Wallace M., Brennan L., Stanton C., Marchesi J.R., Fitzgerald A.P., Shanahan F., Hill C., Ross R.P., O'Toole P.W. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012; 488 (7410): 178−84.Arumugam M., Raes J., Pelletier E., Paslier D. L., Yamada T., Mende D. R. et al. Enterotypes of the human gut microbiome. Nature. 2011; 73: 174–180.Arumugam M., Raes J., Pelletier E., Paslier D.L., Yamada T., Mende D.R. et al. Enterotypes of the human gut microbiome. Nature. 2011; 73: 174−180.O’Toole’s P. W. Categorization of the gut microbiota: enterotypes or gradients? Nature Rev Microbiol. 2012; 10: 591–592.O’Toole’s P.W. Categorization of the gut microbiota: enterotypes or gradients? Nature Rev Microbiol. 2012; 10: 591−592.Loranskaya I.D., Boldyreva M.N., Trofimov D.Yu., Lavrent'eva O.A. Abdominal and parietal microbiota of the colon along with irritable bowel syndrome. Farmateka = Pharmateca. 2013; 18: 61−66.Loranskaya I.D., Boldyreva M.N., Trofimov D.Yu., Lavrent'eva O.A. Abdominal and parietal microbiota of the colon along with irritable bowel syndrome. Farmateka = Pharmateca. 2013; 18: 61−66.Feng T., Elson C. O. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol. 2011; 4: 15–21.Feng T., Elson C.O. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol. 2011; 4: 15–21.Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2009; 16: 53–9.Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2009;16: 53–9.Cammarota G., Ianiro G., Cianci R., Bibbo S., Gasbarrini A., Curro D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. Pharmacol Ther. 2015 Jan 3. pii: S0163–7258 (14)00235–6.Cammarota G., Ianiro G., Cianci R., Bibbò S., Gasbarrini A., Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. Pharmacol Ther. 2015 Jan 3. pii: S0163−7258(14)00235-6.Proal A. D., Albert P. J., Marshall T. G. Autoimmune disease in the era of the metagenome. Autoimmunity Reviews. 2009 Jul; 8 (8): 677–81.Proal A.D., Albert P.J., Marshall T.G. Autoimmune disease in the era of the metagenome. Autoimmunity Reviews. 2009 Jul; 8 (8): 677−81.Devaraj S., Hemarajata P., Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013 Apr; 59 (4): 617–28.Devaraj S., Hemarajata P., Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013 Apr; 59 (4): 617−28.West C. E., Renz H., Jenmalm M. C., Kozyrskyj A. L., Allen K. J., Vuillermin P., Prescott S.L. in-FLAME Microbiome Interest Group; in-FLAME Microbiome Interest Group. The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015 Jan; 135 (1): 3–13.West C.E., Renz H., Jenmalm M.C., Kozyrskyj A.L., Allen K.J., Vuillermin P., Prescott S.L; in-FLAME Microbiome Interest Group; in-FLAME Microbiome Interest Group. The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015 Jan; 135 (1): 3−13.Sanchez M., Panahi S., Tremblay A. Childhood Obesity: A Role for Gut Microbiota? Int J Environ Res Public Health. 2014 Dec 23; 12 (1): 162–175.Sanchez M., Panahi S., Tremblay A. Childhood Obesity: A Role for Gut Microbiota? Int J Environ Res Public Health. 2014 Dec 23; 12 (1): 162−175.Clarke G., Stilling R. M., Kennedy P. J., Stanton C., Cryan J. F., Dinan T. G. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014 Aug; 28 (8): 1221–38.Clarke G., Stilling R.M., Kennedy P.J., Stanton C., Cryan J.F., Dinan T.G. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014 Aug; 28 (8): 1221−38.Yatsunenko T., Rey F. E., Manary M. J., Trehan I., Dominguez Bello M. G., Contreras M., Magris M., Hidalgo G., Baldassano R. N., Anokhin A. P., Heath A. C., Warner B., Reeder J., Kuczynski J., Caporaso J. G., Lozupone C. A., Lauber C., Clemente J. C., Knights D., Knight R., Gordon J. I. Human gut microbiome viewed across age and geography. Nature. 2012; 486: 222–227.Yatsunenko T., Rey F.E., Manary M.J., Trehan I., Dominguez-Bello M.G., Contreras M., Magris M., Hidalgo G., Baldassano R.N., Anokhin A.P., Heath A.C., Warner B., Reeder J., Kuczynski J., Caporaso J.G., Lozupone C.A., Lauber C., Clemente J.C., Knights D., Knight R., Gordon J.I. Human gut microbiome viewed across age and geography. Nature. 2012; 486: 222–227.Koenig J. E., Spor A., Scalfone N., Fricker A. D., Stombaugh J., Knight R., Angenent L. T., Ley R. E. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA. 2011 Mar 15; 108 (Suppl. 1): 4578–85.Koenig J.E., Spor A., Scalfone N., Fricker A.D., Stombaugh J., Knight R., Angenent L.T., Ley R.E. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA. 2011 Mar 15; 108 (Suppl. 1): 4578−85.Chilton S. N., Burton J. P., Reid G. Inclusion of Fermented Foods in Food Guides around the World. Nutrients. 2015; 7 (1): 390–404.Chilton S.N., Burton J.P., Reid G. Inclusion of Fermented Foods in Food Guides around the World. Nutrients. 2015; 7 (1): 390−404.Ozen M., Dinleyici E. C. The history of probiotics: the untold story. Benef Microbes. 2015; 9: 1–7.Ozen M., Dinleyici E.C. The history of probiotics: the untold story. Benef Microbes. 2015; 9: 1−7.Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO. 2011. URL: www.fao.orgHealth and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO. 2011. URL: www.fao.orgRoberfroid M. B. Concepts in functional foods: the case of inulin and oligofructose. J Nutr. 2007; 137: 2709–2716.Roberfroid M.B. Concepts in functional foods: the case of inulin and oligofructose. J Nutr. 2007; 137: 2709−2716.Makarova S.G. Prebiotics as a functional component of child nutrition. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (5): 8–17.Makarova S.G. Prebiotics as a functional component of child nutrition. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (5): 8–17.Gorbach S. L. Probiotics in the third millennium. Digest Liver Dis. 2002; 34 (Suppl. 21): S2–7.Gorbach S.L. Probiotics in the third millennium. Digest Liver Dis. 2002; 34 (Suppl. 21): S2−7.McFarland L. V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006; 101: 812–822.McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006; 101: 812−822.Kornienko E.A. Modern principles of selection of probiotics. Detskie infektsii = Child infections. 2007; 3: 64−69.Kornienko E.A. Modern principles of selection of probiotics. Detskie infektsii = Child infections. 2007; 3: 64−69.Kailasapathy K., Chin J. Survival and therapeutic potential ofprobiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000; 78 (Suppl. 1): 80–88.Kailasapathy K., Chin J. Survival and therapeutic potential ofprobiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000; 78 (Suppl. 1): 80−88.Favier С. F., De Vos W. M., Akkermans A. D. Development of bacterial and bifidobacterial communities infeces ofnewborn babies. Anaerobe. 2003; 9: 219–229.Favier С.F., De Vos W.M., Akkermans A.D. Development of bacterial and bifidobacterial communities infeces ofnewborn babies. Anaerobe. 2003; 9: 219−229.Butel M. J., Suau A., Campeotto F., Magne F., Aires J., Ferraris L., Kalach N., Leroux B., Dupont C. Conditions of bifidobacterial colonization in preterm infants: a prospective analysis. J Ped Gastroenterol Nutr. 2007; 44 (5): 577–582.Butel M.J., Suau A., Campeotto F., Magne F., Aires J., Ferraris L., Kalach N., Leroux B., Dupont C. Conditions of bifidobacterial colonization in preterm infants: a prospective analysis. J Ped Gastroenterol Nutr. 2007; 44 (5): 577−582.Rijkers G. T., Bengmark S., Enck P., Haller D., Herz U., Kalliomaki M., Kudo S., Lenoir-Wijnkoop I., Mercenier A., Mylly luoma E., Rabot S., Rafter J., Szajewska H., Watzl B., Wells J., Wolvers D., Antoine J. M. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr. 2010; 140 (3): 671–6.Rijkers G.T., Bengmark S., Enck P., Haller D., Herz U., Kalliomaki M., Kudo S., Lenoir-Wijnkoop I., Mercenier A., Myllyluoma E., Rabot S., Rafter J., Szajewska H., Watzl B., Wells J., Wolvers D., Antoine J.M. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr. 2010; 140 (3): 671−6.Patten D. A., Laws A. P. Lactobacillus-produced exopolysaccharides and their potential health benefits: a review. Benef Microbes. 2015; 7: 1–15.Patten D.A., Laws A.P. Lactobacillus-produced exopolysaccharides and their potential health benefits: a review. Benef Microbes. 2015; 7: 1−15.Yan F., Polk D. B. Probiotics and immune health. Curr Opin Gastroenterol. 2011; 27: 496–501.Yan F., Polk D.B. Probiotics and immune health. Curr Opin Gastroenterol. 2011; 27: 496−501.Versalovic J. The Human Microbiome and Probiotics: Implications for Pediatrics. Ann Nutr Metab. 2013; 63 (Suppl. 2): 42–52.Versalovic J. The Human Microbiome and Probiotics: Implications for Pediatrics. Ann Nutr Metab. 2013; 63 (Suppl. 2): 42–52.Moayyedi P., Ford A. C., Talley N. J., Foxx-Orenstein A. E., Brandt L. J., Quigley E. M. The efficacy of probi-otics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59: 325–332.Moayyedi P., Ford A.C., Talley N.J., Foxx-Orenstein A.E., Brandt L.J., Quigley E.M. The efficacy of probi-otics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59: 325−332.Issa I., Moucari R. Probiotics for antibiotic-associated diarrhea: Do we have a verdict? World J Gastroenterol. 2014 Dec 21; 20 (47): 17788–17795.Issa I., Moucari R. Probiotics for antibiotic-associated diarrhea: Do we have a verdict? World J Gastroenterol. 2014 Dec 21; 20 (47): 17788−17795.Millar M., Wilks M., Costeloe K. Probiotics for preterm infants? Arch Dis Child Fetal Neonatal. 2003; 88 (5): F354–8.Millar M., Wilks M., Costeloe K. Probiotics for preterm infants? Arch Dis Child Fetal Neonatal. 2003; 88 (5): F354−8.Goldenberg J. Z., Ma S. S., Saxton J. D., Martzen M. R., Vandvik P. O., Thorlund K., Guyatt G. H., Johnston B. C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013; 5: CD006095.Goldenberg J.Z., Ma S.S., Saxton J.D., Martzen M.R., Vandvik P.O., Thorlund K., Guyatt G.H., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013; 5: CD006095.Piescik-Lech M., Shamir R., Guarino A., Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013; 37: 289–303.Piescik-Lech M., Shamir R., Guarino A., Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013; 37: 289–303.Thomas D. W., Greer F. R. Probiotics and prebiotics in pediatrics. Pediatrics. 2010; 126: 1217–1231.Thomas D.W., Greer F.R. Probiotics and prebiotics in pediatrics. Pediatrics. 2010; 126: 1217–1231.Kalliomaki M., Kirjavainen P., Eerola E., Kero P., Salminen S., Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol. 2001 Jan; 107 (1): 129–34.Kalliomäki M., Kirjavainen P., Eerola E., Kero P., Salminen S., Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol. 2001 Jan; 107 (1): 129−34.Bjorksten B., Sepp E., Julge K., Voor T., Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001 Oct; 108 (4): 516–20.Björkstén B., Sepp E., Julge K., Voor T., Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001 Oct; 108 (4): 516−20.Songjinda P., Nakayama J., Tateyama A., Tanaka S., Tsubouchi M., Kiyohara C., Shirakawa T., Sonomoto K. Differences in developing intestinal microbiota between allergic and nonallergic infants: a pilot study in Japan. Biosci Biotechnol Biochem. 2007 Sep; 71 (9): 2338–42.Songjinda P., Nakayama J., Tateyama A., Tanaka S., Tsubouchi M., Kiyohara C., Shirakawa T., Sonomoto K. Differences in developing intestinal microbiota between allergic and non-allergic infants: a pilot study in Japan. Biosci Biotechnol Biochem. 2007 Sep; 71 (9): 2338−42.Kalliomaki M., Salminen S., Poussa T., Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007 Apr; 119 (4): 1019–21.Kalliomäki M., Salminen S., Poussa T., Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007 Apr; 119 (4): 1019−21.Savilahti E. Probiotics in the Treatment and Prevention of Allergies in Children. Biosci Microflora. 2011; 30 (4): 119–128.Savilahti E. Probiotics in the Treatment and Prevention of Allergies in Children. Biosci Microflora. 2011; 30 (4): 119–128.Azad Meghan B., Coneys J. G., Kozyrskyj A. L., Field C. J., Ramsey C. D., Becker A. B., Friesen Carol, Abou-Setta A. M. Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ. 2013; 347: f6471.Azad Meghan B., Coneys J.G., Kozyrskyj A.L., Field C.J., Ramsey C.D., Becker A.B., Friesen Carol, Abou-Setta A.M. Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ. 2013; 347: f6471.Food Allergy and Anaphylaxis Guidelines. EAACI. 2014. 278 p.Food Allergy and Anaphylaxis Guidelines. EAACI. 2014. 278 p.Tang R. B., Chang J. K., Chen H. L. Can probiotics be used to treat allergic diseases? J Chin Med Assoc. 2015 Jan 6. Р. S1726–4901.Tang R.B., Chang J.K., Chen H.L. Can probiotics be used to treat allergic diseases? J Chin Med Assoc. 2015 Jan 6. Р. S1726−4901.Fiocchi A., Burks W., Bahna S. L., Bielory L., Boyle R. J., Cocco R., Dreborg S., Goodman R., Kuitunen M., Haahtela T., Heine R. G., Lack G., Osborn D. A., Sampson H., Tannock G. W., Lee B. W. Clinical use of probiotics in pediatric allergy (CUPPA): a World Allergy Organization position paper. World Allergy Organ J. 2012; 5: 148–167.Fiocchi A., Burks W., Bahna S.L., Bielory L., Boyle R.J., Cocco R., Dreborg S., Goodman R., Kuitunen M., Haahtela T., Heine R.G., Lack G., Osborn D.A., Sampson H., Tannock G.W., Lee B.W. Clinical use of probiotics in pediatric allergy (CUPPA): a World Allergy Organization position paper. World Allergy Organ J. 2012; 5: 148–167.Isolauri E. Dietary modification of atopic disease: of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol. 2004; 50 (3): 391–404.Isolauri E. Dietary modification of atopic disease: of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD) / American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol. 2004; 50 (3): 391−404.Boyle R. J., Bath-Hextall F. J., Leonardi-Bee J., Murrell D. F., Tang M. L. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008 Oct 8; 4: CD006135.Boyle R.J., Bath-Hextall F.J., Leonardi-Bee J., Murrell D.F., Tang M.L. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008 Oct 8; 4: CD006135.Guandalini S., Magazzu G., Chiaro A., La Balestra V., Di Nardo G., Gopalan S., Sibal A., Romano C., Canani R. B., Lionetti P., Setty M. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, ran- domized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010; 51: 24–30.Guandalini S., Magazzu G., Chiaro A., La Balestra V., Di Nardo G., Gopalan S., Sibal A., Ro- mano C., Canani R.B., Lionetti P., Setty M. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, ran- domized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010; 51: 24–30.Bausserman M., Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005; 147: 197–201.Bausserman M., Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005; 147: 197–201.Mayer E. A. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011; 12: 453–466.Mayer E.A. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011; 12: 453–466.Morgan X. C., Tickle T. L., Sokol H., Gevers D., Devaney K. L., Ward D. V., Reyes J. A., Shah S. A., LeLeiko N., Snapper S. B., Bousvaros A., Korzenik J., Sands B. E., Xavier R. J., Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012; 13: 76–79.Morgan X.C., Tickle T.L., Sokol H., Gevers D., Devaney K.L., Ward D.V., Reyes J.A., Shah S.A., LeLeiko N., Snapper S.B., Bousvaros A., Korzenik J., Sands B.E., Xavier R.J., Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012; 13: 76−79.Fernandez-Feo M., Wei G., Blumenkranz G., Dewhirst F. E., Schuppan D., Oppenheim F. G., Helmerhorst E. J. The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity. Clin Microbiol Infect. 2013; 19: E386–E394.Fernandez-Feo M., Wei G., Blumenkranz G., Dewhirst F.E., Schuppan D., Oppenheim F.G., Helmerhorst E.J. The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity. Clin Microbiol Infect. 2013; 19: E386–E394.Franz M. J., VanWormer J. J., Crain A. L., Boucher J. L., Histon T., Caplan W., Bowman J. D., Pronk N. P. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007; 107: 1755–67.Franz M.J., VanWormer J.J., Crain A.L., Boucher J.L., Histon T., Caplan W., Bowman J.D., Pronk N.P. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007; 107: 1755–67.Westrate J. A., van Poppel G., Verschuren P. M. Functional foods, trends and future. Br J Nutr. 2002; 88: S233–5.Westrate J.A., van Poppel G., Verschuren P.M. Functional foods, trends and future. Br J Nutr. 2002; 88: S233–5.Han J. L., Lin H. L. Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World J Gastroenterol. 2014 Dec 21; 20 (47): 17737–17745.Han J.L., Lin H.L. Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World J Gastroenterol. 2014 Dec 21; 20 (47): 17737−17745.

The authors declare that there are no conflicts of interest present.